Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 14 (16), 1783-7

Molecular Approaches for Neuropathic Pain Treatment


Molecular Approaches for Neuropathic Pain Treatment

Dario Siniscalco et al. Curr Med Chem.


Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system. It is estimated that 75-150 million people in the United States have a chronic pain disorder. Neuropathic pain has a great impact on the quality of life. It is debilitating and often has an associated degree of depression that contributes to decreasing human wellbeing. Moreover, the management of chronic pain is costly to the health care system. The United States Congress has declared the present decade (2001-2010) as the "Decade of Pain Control and Research", making pain a national healthcare priority. In Europe, statistics provided by the International Association on the Study of Pain (IASP) and the European Federation of the IASP Chapters (EFIC) indicate that one in five people suffer from moderate to severe chronic pain, and that one in three are unable or less able to maintain an independent lifestyle due to their pain. Between one-half and two-thirds of people with chronic pain are less able or unable to exercise, enjoy normal sleep, perform household chores, attend social activities, drive a car, walk or have sexual relations. The effect of pain means that one in four reports that relationships with family and friends are strained or broken, according to the IASP/EFIC data. Neuropathic pain treatment is extremely difficult. Neuropathic pain is a very complex disease, involving several molecular pathways. Excitatory or inhibitory pathways controlling neuropathic pain development show altered gene expression, caused by peripheral nerve injury. Current available drugs are usually not acting on the several mechanisms underlying the generation and propagation of pain. Nowadays, pain research is directing on new molecular methods, such as gene therapy, stem cell therapy and viral vectors for delivery of biologic antinociceptive molecules. These methods could provide a new therapeutic approach to neuropathic pain relief.

Similar articles

  • Stem Cell Therapy for Neuropathic Pain Treatment
    D Siniscalco et al. J Stem Cells Regen Med 3 (1), 2-11. PMID 24693013.
    Pain initiated or caused by a primary lesion or dysfunction in the nervous system is defined as neuropathic pain. About 75 -150 million people in the United States are su …
  • Role of Neurotrophins in Neuropathic Pain
    D Siniscalco et al. Curr Neuropharmacol 9 (4), 523-9. PMID 22654713.
    Neurotrophins (NTs) belong to a family of structurally and functionally related proteins, they are the subsets of neurotrophic factors. Neurotrophins are responsible for …
  • Neuropathic Pain: Is the End of Suffering Starting in the Gene Therapy?
    D Siniscalco et al. Curr Drug Targets 6 (1), 75-80. PMID 15720215. - Review
    Neuropathic pain is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system. It is a devastating and difficult to manage consequence …
  • [Neuropathic Pain]
    N Bebek et al. Agri 19 (3), 5-10. PMID 18095193. - Review
    Neuropathic pain is caused by functional abnormalities of structural lesions or dysfunction in the peripheral or central nervous system, and occurs without peripheral noc …
  • Spinal Cord Stimulation for Neuropathic Pain: An Evidence-Based Analysis
    Medical Advisory Secretariat. Ont Health Technol Assess Ser 5 (4), 1-78. PMID 23074473.
    SCS may be considered for patients with chronic, neuropathic pain for whom standard pain treatments have failed and when there is no indication for surgical intervention …
See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles